Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care

SkylineDx California United States of America United Kingdom Netherlands

and www.merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase the access. In the United States, Tempus is commercializing Tempus Merlin test.
Quest Diagnostics launched their own LDT version of the CP-GEP model in the United States under the brand name MelaNodal Predict™.

About SkylineDx
SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit www.skylinedx.com.

 

Footnotes:

T. Wong et. al. Predictive Performance of the Clinicopathologic Gene Expression Profile
(CP-GEP) in Identifying Cutaneous Melanoma Patients for Whom Sentinel Lymph Node Biopsy is Unnecessary: A Systematic Review and Meta-Analysis. https://falconprogram.com/files/AMC2024%20CP-GEP%20Poster.pdfUnderstanding Melanoma Staging - Melanoma Research AllianceSondak et al., Prospective multicenter evaluation (MERLIN_001 trial) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma https://falconprogram.com/files/SMR%202024%20Abstract%20MERLIN_001.pdf

View original content:https://www.prnewswire.co.uk/news-releases/independent-meta-analyses-by-melanoma-institute-of-australia-on-cp-gep-model-in-melanoma-care-302286457.html

@ prnewswire.co.uk